AbbVie

News

BMS hands back rights to cancer ADC licensed from Eisai

Bristol-Myers Squibb has ended a $3.1 billion strategic collaboration with Eisai focusing on antibody-drug conjugates (ADCs) and returned rights to the lead drug in the alliance.

News

AbbVie breaks new ground for IL-23 drug Skyrizi in IBD

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD) –

News

AbbVie licenses FutureGen IBD drug in $1.7bn deal

The high value attached by pharma companies to inflammation and immunology (I&I) programmes is on display once again, as AbbVie agrees a deal worth up to $1.7 billion for an inflammator

News

AbbVie takes option on Gilgamesh CNS drugs in $2bn deal

AbbVie has agreed to pay $65 million on an option deal with start-up Gilgamesh Pharma, lining up rights to neuroplastogen compounds that can improve neuroplasticity - the

R&D

Emergence of ADCs as the “hot, new technology”

The recent acquisition of ImmunoGen by AbbVie, which followed the earlier acquisition of Seagen by Pfizer, has brought renewed attention to antibody-drug conjugates (ADCs), highlighting the

News

Cerevel Parkinson’s data adds lustre to AbbVie acquisition

Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie, wh

BMS hands back rights to cancer ADC licensed from Eisai

AbbVie breaks new ground for IL-23 drug Skyrizi in IBD

AbbVie licenses FutureGen IBD drug in $1.7bn deal

AbbVie takes option on Gilgamesh CNS drugs in $2bn deal

Emergence of ADCs as the “hot, new technology”

Cerevel Parkinson’s data adds lustre to AbbVie acquisition

BMS's Breyanzi is first CAR-T for marginal zone lymphoma

How to meet your physicians where they are online

AbbVie

Editor's Picks